Unknown statusInterventionalPhase 2Last updated Jul 22, 2024

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy

Overview

ClinicalTrials.gov ID: NCT05013099
Lead Sponsor: ImaginAb, Inc.INDUSTRY
Brief Summary: The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Study Type

Status

Overall Status: Unknown status
Start Date: Dec 9, 2021Actual
Primary Completion Date: Jul 2025Estimated
Completion Date: Jul 2025Estimated

Study Record Dates

First Submitted: Jul 30, 2021
First Submitted that Met QC Criteria: Aug 18, 2021
First Posted: Aug 19, 2021Actual
Last Update Submitted that Met QC Criteria: Jul 19, 2024
Last Update Posted: Jul 22, 2024Actual
Last Verified: Jul 2024

NCT05279027Active, not recruiting

Zr89 + PET Companion Trial

NCT06650163Recruiting

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

NCT05744128Terminated

CD8 Minibody Repeatability Study

NCT06534190Recruiting

CD8 PET Imaging in Metastatic Solid Tumours

NCT03107663Completed

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

NCT06863233Recruiting

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer